Shares in Genentech Inc. sagged Tuesday, after the company said its blockbuster cancer drug Rituxan failed to curb symptoms of the debilitating autoimmune disorder called systemic lupus ...

The latest comes from a promising study that found Rituxan cut the risk of relapse in Multiple Sclerosis patients in half. Rituxan, sold by Genentech and Biogen Idec, targets immune system cells ...

received two new regulatory approvals covering the blood cancer drug Rituxan. The Food and Drug Administration cleared Rituxan to treat CD20-positive, B-cell non-Hodgkin's lymphoma in patients who ...

The study is likely to spur the already substantial “off-label” use of Rituxan among patients with the fast-spreading form of non-Hodgkin’s lymphoma. Rituxan, among the best-selling cancer ...

Roche RHHBY announced that the late-stage study, PEMPHIX, on its rheumatoid arthritis (RA) drug, MabThera/Rituxan for the indication of pemphigus vulgaris (PV) was successful. We note that Rituxan ...

More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the ...

Roche has received the Food and Drug Administration’s clearance for Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis, or GPA and ...

SAN FRANCISCO (MarketWatch) -- Biogen Idec Inc. on Tuesday reported results from a Phase II clinical study in which it was shown that galiximab may be used in combination with Rituxan and the ...

Sober news from Genentech today: A fatal case of progressive multifocal leukoencephalopathy, or PML, has cropped up in an arthritis patient treated with the blockbuster drug Rituxan. The patient was ...

Rituxan is already one of the most successful biotech-derived cancer drugs ever created. Now, early research data suggest the drug also might prove to be effective as a treatment for rheumatoid ...

The disease can be life threatening. Phase 3 study results released last March demonstrated Rituxan substantialy improved pemphigus vulgaris remission rates and successful tapering. The Food and ...